Philips Healthcare Medical Device Companies Analysis Report

The IPO for Philips’ Lighting business and the sale of Lumileds were symbolic events, which served to solidify Philips' status as a health technology company. Philips has chosen to proactively de-diversify its Lighting business and lighting components business in order to prioritise its healthcare units and increase its focus in areas such as digital health, which offer the greatest growth potential. Philips' corporate strategy is intended to maximise growth opportunities for its health technology portfolio through operational performance improvement, long-term strategic partnerships and adopting a solutions based approach, which combines suites of systems, smart devices, software and services. Philips’s future results will depend on the execution of this strategy as well as its ability to capitalise on market opportunities in growth geographies such as China and Russia.

Medical Device Company Analysis profiles help understand and investigate competitors, potential partners or investment opportunities within the medical device market.

With industry-leading analysis of over 50 key players and subsidiaries, each profile is a full company review including latest corporate activities, mergers & acquisitions, product development, and R&D as well as in-depth five year financial analysis, where available.


Sign up to download the Philips Healthcare Medical Device Companies Analysis Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Philips Healthcare Medical Device Companies Analysis Report
Product Price

The Medical Device Companies Analysis (MDCA) portfolio provides a concise yet comprehensive review of the leading players in the medical device industry. Key sections include Strategic Focus, Financial Review, Market Assessment, Product Analysis, Research & Development, Operations and Agreements. Each chapter is summarised in a forward-looking BMI View, which provides an impartial opinion on the company’s outlook.

As a set of business reports, the MDCA portfolio contains readily digestible analysis; for example, company results are contextualised with competitor information. Recently added datasets include corporate transactions, financial ratios and FDA 510(k) clearances, where available. The MDCA portfolio is well positioned to support the evaluation of competitors, partners and investment decisions within the medical device market.